Altretamine
From Wikipedia, the free encyclopedia
 |
|
|
Altretamine
|
|
| Systematic (IUPAC) name | |
| N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C9H18N6 |
| Mol. mass | 210.28 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 94% |
| Metabolism | ? |
| Half life | 4.7-10.2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Altretamine (also hexalen) is a drug that is used to treat refractory ovarian cancer. It is not considered a first-line treatment,[1] but it can be useful as salvage therapy.[2] It also has the advantage of being less toxic than other drugs used for treating refractory ovarian cancer.[3]
The precise mechanism by which altretamine exerts its anti-cancer effect is unknown, but it is classified by MeSH as an alkylating antineoplastic agent. Hydroxymethylmelamines are the active metabolite.[4]
It was approved by the FDA in 1990.
[edit] Side effects
Side effects include nausea, vomiting, diarrhea and neurotoxicity.
[edit] References
- ^ Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A (2003). "Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study". Gynecol. Oncol. 88 (2): 118–22. PMID 12586589.
- ^ Chan JK, Loizzi V, Manetta A, Berman ML (2004). "Oral altretamine used as salvage therapy in recurrent ovarian cancer". Gynecol. Oncol. 92 (1): 368–71. PMID 14751188.
- ^ Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J. Clin. Oncol. 31 (2): 69–73. PMID 11302345.
- ^ Damia G, D'Incalci M (1995). "Clinical pharmacokinetics of altretamine". Clinical pharmacokinetics 28 (6): 439–48. PMID 7656502.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
